4/A//SEC Filing
KLARMAN SETH A 4/A
Accession 0001567619-21-017206
CIK 0001693415other
Filed
Sep 15, 8:00 PM ET
Accepted
Sep 16, 5:43 PM ET
Size
10.0 KB
Accession
0001567619-21-017206
Insider Transaction Report
Form 4/AAmended
BAUPOST GROUP LLC/MA
10% Owner
Transactions
- Other
Common Stock
2021-09-14$38.00/sh−18,044,239$685,681,082→ 0 total(indirect: See footnote 1 and 2)
Baupost Group GP, L.L.C.
10% Owner
Transactions
- Other
Common Stock
2021-09-14$38.00/sh−18,044,239$685,681,082→ 0 total(indirect: See footnote 1 and 2)
KLARMAN SETH A
10% Owner
Transactions
- Other
Common Stock
2021-09-14$38.00/sh−18,044,239$685,681,082→ 0 total(indirect: See footnote 1 and 2)
Footnotes (3)
- [F1]This statement on Form 4 is being jointly filed by The Baupost Group, L.L.C. ("Baupost"), Baupost Group GP, L.L.C. ("BG GP") and Seth A. Klarman ("Mr. Klarman") (collectively, the "Reporting Persons"). Baupost is a registered investment adviser. The principal business of Baupost is to act as an investment adviser to various private investment limited partnerships. BG GP, as the manager of Baupost, and Mr. Klarman, as the sole managing member of BG GP and a controlling person of Baupost, may be deemed to have beneficial ownership under Section 13 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), of the securities beneficially owned by Baupost. Securities reported on this Form 4 as being beneficially owned by Baupost were purchased on behalf of certain of such partnerships.
- [F2](Continued from Footnote 1) The Reporting Persons disclaim beneficial ownership of the securities indicated except to the extent of their pecuniary interest therein, and the reporting herein of such securities shall not be construed as an admission that the Reporting Persons are the beneficial owners thereof for purposes of Section 16 of the Exchange Act or for any other purpose.
- [F3]On September 14, 2021, the Agreement and Plan of Merger among Sanofi, Vector Merger Sub Inc. and Translate Bio Inc. ("Merger Agreement") was consummated and Sanofi completed its acquisition of the Issuer as described in the 8-K filed by the Issuer on September 14, 2021, and incorporated herein by reference. In connection with the consummation of the merger, all shares of Common Stock of the Issuer held by the Reporting Persons were acquired at the tender offer price of $38.00 per share.
Documents
Issuer
Translate Bio, Inc.
CIK 0001693415
Entity typeother
IncorporatedMA
Related Parties
1- filerCIK 0000899869
Filing Metadata
- Form type
- 4/A
- Filed
- Sep 15, 8:00 PM ET
- Accepted
- Sep 16, 5:43 PM ET
- Size
- 10.0 KB